"EXTREmers are produced using our newly developed, high-throughput oligonucleotide synthesizer that incorporates highly efficient reagent delivery systems, cycle-optimization, and downstream processes to ensure that each coupling reaction achieves greater than 99.5% efficiency," said Jeff Nelson, Head of Process Development for High-Throughput Synthesis at Eurofins Genomics. "Our initial experiments have shown that these oligos offer a higher probability of success than those offered by comparable products when evaluated in cloning applications."
More information about EXTREmers is available at http://www.eurofinsgenomics.com/en/products/dnarna-synthesis/extremers.aspx.
About Eurofins Genomics
Eurofins Genomics company is an international provider of DNA sequencing services, genotyping services, DNA synthesis products, and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological, and research markets. Eurofins Genomics operates leading R&D and production sites in the USA, Canada, Germany, India, and Japan.
Eurofins Genomics is the genomic services brand of the Eurofins Group, the worldwide leader in food, environmental and pharmaceutical testing. With 25,000 staff in over 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
© Eurofins MWG Operon, LLC, a Eurofins Genomics Company
Logo - http://photos.prnewswire.com/prnh/20161004/415145LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eurofins-genomics-launches-extremers--extremely-long-oligonucleotides-300376190.html
SOURCE Eurofins Genomics